105 - N Nuñez y col.

Nicolás Nuñez, César Casin, Jacqueline Nuñez, María Laspiur, Juana Rodriguez, Norberto Zelaschi, Luis Zieher Bibliografía • Akiskal, H. S., Bourgeois, M. L., Angst, J., Post, R., Möller, H.-J., & Hirschfeld, R. (2000). Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. Journal of affective disorders, 59, S5-S30. • Alvano, S. A. (2010a). Trastornos depresivos y de ansiedad: aspectos neurobiologicos, clinico y terapeuticos. Editorial Sciens, 226-227. • Alvano, S. A. (2010b). Trastornos depresivos y de ansiedad: Aspectos neurobiologicos, clinicos y terapeuticos., Capitulo 15.A.Policella, 201. Angst, J., Sellaro, R., Stassen, H. H., & Gamma, A. (2005). Diagnostic conversion from depression to bipolar disorders: results of a long-term prospective study of hospital admissions. Journal of affective disorders, 84(2), 149-157. • Balestri, M., Calati, R., Souery, D., Kautzky, A., Kasper, S., Montgomery, S., Serretti, A. (2016). Socio-demographic and clinical predictors of treatment resistant depression: A prospective European multicenter study. Journal of affective disorders, 189, 224-232. • Berlim, M. T., & Turecki, G. (2007). Definition, Assessment, and Staging of Treatment—Resistant Refractory Major Depression: A Review of Current Concepts and Methods. The Canadian Journal of Psychiatry, 52(1), 46-54. • Bowden, C. L. (2005). A different depression: clinical distinctions between bipolar and unipolar depression. Journal of affective disorders, 84(2), 117-125. • Bremner, J. D., Vythilingam, M., Vermetten, E., Nazeer, A., Adil, J., Khan, S., Charney, D. S. (2002). Reduced volume of orbitofrontal cortex in major depression. Biological psychiatry, 51(4), 273-279. • Brown, S., Peet, E., Manuck, S., Williamson, D., Dahl, R., Ferrell, R., & Hariri, A. (2005). A regulatory variant of the human tryptophan hydroxylase-2 gene biases amygdala reactivity. Molecular psychiatry, 10(9), 884-888. • Campbell, S., Marriott, M., Nahmias, C., & MacQueen, G. M. (2004). Lower hippocampal volume in patients suffering from depression: a meta-analysis. American Journal of Psychiatry, 161(4), 598-607. • Capuron, L., Raison, C. L., Musselman, D. L., Lawson, D. H., Nemeroff, C. B., & Miller, A. H. (2003). Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. American Journal of Psychiatry. • Caspi, A., Sugden, K., Moffitt, T. E., Taylor, A., Craig, I. W., Harrington, H., . . . Braithwaite, A. (2003). Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science, 301(5631), 386-389. • Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., McGuire, H. (2009). Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. The Lancet, 373(9665), 746-758. • Deakin, B., & Dursun, S. (2002). Optimizing antidepressant treatment: efficacy and tolerability. International clinical psychopharmacology, 17, S13- S24. • Dold, M., & Kasper, S. (2016). Evidence-based pharmacotherapy of treatment-resistant unipolar depression. International Journal of Psychiatry in Clinical Practice, 1- 11. • Drevets, M., Wayne C. (1998). Functional neuroimaging studies of depression: the anatomy of melancholia. Annual review of medicine, 49(1), 341-361. • DSM-5. (2013). Diagnostic and statistical manual of mental disorders (DSM-5®): American Psychiatric Pub. • Fagiolini, A., & Kupfer, D. J. (2003). Is treatment-resistant depression a unique subtype of depression? Biological psychiatry, 53(8), 640-648. • Fava, M. (2003). Diagnosis and definition of treatmentresistant depression. Biological psychiatry, 53(8), 649- 659. • Fava, M., & Davidson, K. G. (1996). Definition and epidemiology of treatment-resistant depression. Psychiatric Clinics of North America, 19(2), 179-200. • Fekadu, A., Wooderson, S. C., Markopoulo, K., Donaldson, C., Papadopoulos, A., & Cleare, A. J. (2009). What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies. Journal of affective disorders, 116(1), 4-11. • Ghaemi, S. N., & Ko, J. Y. (2002). “Cade's disease” and beyond: misdiagnosis, antidepressant use, and a proposed definition for bipolar spectrum disorder. The Canadian Journal of Psychiatry, 47(2), 125-134. • Ghaemi, S. N., Rosenquist, K. J., Ko, J. Y., Baldassano, C. F., Kontos, N. J., & Baldessarini, R. J. (2004). Antidepressant treatment in bipolar versus unipolar depression. American Journal of Psychiatry, 161(1), 163-165. • Iacoviello, B. M., Alloy, L. B., Abramson, L. Y., & Choi, J. Y. (2010). The early course of depression: a longitudinal investigation of prodromal symptoms and their relation to the symptomatic course of depressive episodes. Journal of abnormal psychology, 119(3), 459. • Kasper, S., Akimova, E., & Montgomery, S. (2013). The Role of Atypical Antipsychotics in Inadequate‐response and Treatment‐resistant Depression. Treatment-resistant depression, 107-128. • Kautzky, A. B.-M. P. K. G. V. T. S. D. M. S. M. J. Z. J. S. A. L. R. K. S. (2017). A new prediction Model for Evaluating Treatment Resistant Depression. Journal of Clinical Psychiatry. doi:10.4088/JCP.15m10381. • Kennedy, N., Abbott, R., & Paykel, E. (2003). Remission and recurrence of depression in the maintenance era: long-term outcome in a Cambridge cohort. Psychological medicine, 33(05), 827-838. • Kessler, R. C., & Merikangas, K. R. (2004). The National Comorbidity Survey Replication (NCS‐R): background and aims. International journal of methods in psychiatric research, 13(2), 60-68. • Klimek, V., Stockmeier, C., Overholser, J., Meltzer, H. Y., Kalka, S., Dilley, G., & Ordway, G. A. (1997). Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. The Journal of Neuroscience, 17(21), 8451-8458. • Kornstein, S. G., & Schneider, R. K. (2001). Clinical features of treatment-resistant depression. Journal of Clinical Psychiatry, 62, 18-25. • Li, B., Piriz, J., Mirrione, M., Chung, C., Proulx, C. D., Schulz, D., Malinow, R. (2011). Synaptic potentiation onto habenula neurons in the learned helplessness model of depression. Nature, 470(7335), 535-539. • Maes, M. (2011). Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Progress in Neuro- Psychopharmacology and Biological Psychiatry, 35(3), 664-675. • Malhi, G., Parker, G., Crawford, J., Wilhelm, K., & Mitchell, P. (2005). Treatment‐resistant depression: resistant to definition? Acta Psychiatrica Scandinavica, 112(4), 302-309. • Nemeroff, C. B. (2007). Prevalence and management of treatment-resistant depression. Journal of Clinical Psychiatry, 68(8), 17. • Østergaard, S. D., Jensen, S., & Bech, P. (2011). The heterogeneity of the depressive syndrome: when numbers get serious. Acta Psychiatrica Scandinavica, 124(6), 495-496. • Petersen, T., Papakostas, G. I., Mahal, Y., Guyker, W. M., Beaumont, E. C., Alpert, J. E., Nierenberg, A. A. (2004). Psychosocial functioning in patients with treatment resistant depression. European psychiatry, 19(4), 196-201. • Petersen, T., Papakostas, G. I., Posternak, M. A., Kant, A., Guyker, W. M., Iosifescu, D. V., Fava, M. (2005). Empirical testing of two models for staging antidepressant treatment resistance. Journal of clinical psychopharmacology, 25(4), 336-341. • Porcelli, S., Fabbri, C., & Serretti, A. (2012). Metaanalysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. European Neuropsychopharmacology, 22(4), 239- 258. • Rost, K., Zhang, M., Fortney, J., Smith, J., Coyne, J., & Smith, G. R. (1998). Persistently poor outcomes of undetected major depression in primary care. General hospital psychiatry, 20(1), 12-20. • Russell, J. M., Hawkins, K., Ozminkowski, R. J., Orsini, L., Crown, W. H., Kennedy, S., Rush, A. J. (2004). The cost consequences of treatment-resistant depression. The Journal of clinical psychiatry, 65(3), 341-347. • Russo, S. J., & Nestler, E. J. (2013). The brain reward circuitry in mood disorders. Nature Reviews Neuroscience, 14(9), 609-625. • Sackeim, H. A. (2001). The definition and meaning of treatment-resistant depression. Journal of Clinical Psychiatry, 62, 10-17. • Sanacora, G., Gueorguieva, R., Epperson, C. N., Wu, Y.- T., Appel, M., Rothman, D. L., Mason, G. F. (2004). Subtype-specific alterations of γ-aminobutyric acid and glutamatein patients with major depression. Archives of general psychiatry, 61(7), 705-713. • Schatzberg, A. F., & Lindley, S. (2008). Glucocorticoid antagonists in neuropsychotic disorders. European journal of pharmacology, 583(2), 358-364. • Schlaepfer, T. E., Ågren, H., Monteleone, P., Gasto, C., Pitchot, W., Rouillon, F., Kasper, S. (2012). The hidden third: improving outcome in treatment-resistant depression. Journal of Psychopharmacology, 26(5), 587-602. • Sequeira, A., Mamdani, F., Ernst, C., Vawter, M. P., Bunney, W. E., Lebel, V., Benkelfat, C. (2009). Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression. PloS one, 4(8), e6585. • Serretti, A., Kato, M., De Ronchi, D., & Kinoshita, T. (2007). Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Molecular psychiatry, 12(3), 247-257. • Sharma, V., Khan, M., & Smith, A. (2005). A closer look at treatment resistant depression: is it due to a bipolar diathesis? Journal of affective disorders, 84(2), 251- 257. • Sheline, Y. I., Gado, M. H., & Price, J. L. (1998). Amygdala core nuclei volumes are decreased in recurrent major depression. Neuroreport, 9(9), 2023-2028. • Souery, D., Amsterdam, J., De Montigny, C., Lecrubier, Y., Montgomery, S., Lipp, O., Mendlewicz, J. (1999). Treatment resistant depression: methodological overview and operational criteria. European Neuropsychopharmacology, 9(1), 83-91. • Souery, D., Oswald, P., Massat, I., Bailer, U., Bollen, J., Demyttenaere, K., Serretti, A. (2007). Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. Journal of Clinical Psychiatry, 68(7), 1062-1070. • Souery, D., Papakostas, G. I., & Trivedi, M. H. (2006). Treatment-resistant depression. Journal of Clinical Psychiatry, 67, 16. • Souery, D., Pichot, W., Kasper, S., & Montgomery, S. (2013). Treatment‐resistant Depression. Treatment - resistant depression, 1-20. • Taliaz, D., Stall, N., Dar, D., & Zangen, A. (2010). Knockdown of brain-derived neurotrophic factor in specific brain sites precipitates behaviors associated with depression and reduces neurogenesis. Molecular psychiatry, 15(1), 80-92. • Thase, M. E., & Rush, A. J. (1997). When at first you don't succeed: sequential strategies for antidepressant nonresponders. The Journal of clinical psychiatry. • Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Biggs, M. M. (2006). Medication augmentation after the failure of SSRIs for depression. New England Journal of Medicine, 354(12), 1243-1252. • Vergunst, F. K., Fekadu, A., Wooderson, S. C., Tunnard, C. S., Rane, L. J., Markopoulou, K., & Cleare, A. J. (2013). Longitudinal course of symptom severity and fluctuation in patients with treatment-resistant unipolar and bipolar depression. Psychiatry research, 207(3), 143-149. • Warden, D., Rush, A. J., Trivedi, M. H., Fava, M., & Wisniewski, S. R. (2007). The STAR* D Project results: a comprehensive review of findings. Current psychiatry reports, 9(6), 449-459. • Xiang, L., Szebeni, K., Szebeni, A., Klimek, V., Stockmeier, C. A., Karolewicz, B., Ordway, G. A. (2008). Dopamine receptor gene expression in human amygdaloid nuclei: elevated D4 receptor mRNA in major depression. Brain research, 1207, 214-224. • Zieher, L. e. a. (2010). Tratado de psicofarmacologia y neurociencias: trastornos depresivos. Parte I: neurologia y consideraciones diagnosticas. • Zieher, L. e. a. (2016). La moderna ciencia de redes y la fisiopatología de los trastornos psiquiátricos. SCIENS Vol. 100. 22 // EDITORIAL SCIENS